MHSPC Clinical Decision-Making: Applying Trial Data

Advancements in Treating Metastatic Hormone-sensitive Prostate Cancer

Metastatic hormone-sensitive prostate cancer (mHSPC)‍ now has a growing range of effective treatment options. These typically ‍involve combining androgen deprivation therapy (ADT) with ⁤newer hormonal agents. ⁣Recent advancements include the ⁣approval of abiraterone, apalutamide, enzalutamide, and darolutamide, offering clinicians more tools to personalize treatment plans.

Case Study: ⁢Managing Recurrence

A 67-year-old male initially presented with urinary retention, fatigue, and⁢ decreased appetite.⁤ He had a history of well-controlled hypertension and hyperlipidemia, and no family history of prostate cancer.Initial diagnosis revealed high-grade prostate cancer ‍(Gleason⁢ score 8 [4+4]) ⁤with involvement⁣ in ⁣10 of 12 core biopsies, and a PSA of 150 ⁣ng/mL.

The patient underwent a triumphant robotic radical prostatectomy, achieving a PSA of less ⁤than 0.1 ng/mL. Subsequent CT and bone scans showed no⁤ evidence of residual disease.

Unfortunately, thirteen months later, the disease recurred. Despite being asymptomatic with a good performance status (ECOG 0), follow-up revealed a PSA of 35 ng/mL and CT scans showed enlarged lymph nodes and‍ bone lesions.

Treatment Considerations

The patient was referred to a medical oncologist for further evaluation and ⁤treatment ‍planning. ⁣The discussion⁤ focused on available treatment options, including ⁣those involving androgen deprivation therapy (ADT) ⁤in combination with newer ⁤agents. Careful consideration of the patient’s overall health and preferences is ⁤crucial in selecting the most appropriate approach.

Value to ⁣Patients: These advancements provide men with mHSPC more effective treatment options, potentially extending life expectancy and improving quality of life. ⁣The ability to personalize treatment based on individual characteristics and disease progression ⁤is a meaningful benefit.